跳转至内容
Merck
CN

Z103

Sigma-Aldrich

Zolpidem

≥98% (HPLC), solid, benzodiazepine receptor agonist

别名:

N,N,6-Trimethyl-2-(4-methylphenyl)-imidazo[1,2-a]pyridine-3-acetamide

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C19H21N3O
CAS号:
分子量:
307.39
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77

产品名称

Zolpidem, ≥98% (HPLC), solid

质量水平

方案

≥98% (HPLC)

表单

solid

药品控制

USDEA Schedule IV; Home Office Schedule 4.1; psychotrope (France); kontrollierte Droge in Deutschland; regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)

颜色

white

溶解性

45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 0.3 mg/mL
DMSO: >10 mg/mL
ethanol: 50 mg/mL
methanol: 50 mg/mL
H2O: insoluble
dilute aqueous base: insoluble

创始人

Sanofi Aventis

SMILES字符串

CC1=CN2C(C=C1)=NC(C3=CC=C(C)C=C3)=C2CC(N(C)C)=O

InChI

1S/C19H21N3O/c1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19/h5-10,12H,11H2,1-4H3

InChI key

ZAFYATHCZYHLPB-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

生化/生理作用

Potent and selective agonist for the benzodiazepine receptor associated with the GABAA receptor; hypnotic.

特点和优势

This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the GABAA Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

象形图

Exclamation markEnvironment

警示用语:

Warning

危险声明

危险分类

Acute Tox. 4 Oral - Aquatic Chronic 2 - STOT SE 3

靶器官

Central nervous system

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Gloves, type N95 (US)

法规信息

监管及禁止进口产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Hsin-I Shih et al.
Medicine, 94(17), e809-e809 (2015-05-02)
We evaluate the effects of zolpidem use to develop dementia or Alzheimer disease from the Taiwan National Health Insurance Research Database (NHIRD).A retrospective population-based nested case-control study. Newly diagnosed dementia patients 65 years and older and controls were sampled. A
Eunmi Kim et al.
Forensic science international, 269, 50-55 (2016-11-21)
The southern area of South Korea consists of three parts; Busan, Ulsan and Gyeongsangnam-do. Busan Institute of National Forensic Service (NFS) performed about 50,000 cases throughout the southern area in 2014, occupying over 15% of total cases covered by NFS.
Cheng-Tai Li et al.
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 12(11), 1453-1459 (2016-08-30)
The present single-dose, parallel-group, randomized, double-blind, placebo-controlled study is to evaluate the pharmacokinetics, tolerability and safety of zolpidem tartrate nasal spray (ZNS) as compared to placebo in healthy subjects. Thirty-six healthy subjects participated in this study, with 19 male and
Sara C Mednick et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 33(10), 4494-4504 (2013-03-08)
An important function of sleep is the consolidation of memories, and features of sleep, such as rapid eye movement (REM) or sleep spindles, have been shown to correlate with improvements in discrete memory domains. Because of the methodological difficulties in
Ji-Yeong Byeon et al.
Archives of pharmacal research, 41(8), 861-866 (2018-08-18)
Zolpidem is indicated for the short-term treatment of insomnia and it is predominantly metabolized by CYP3A4, and to a lesser extent by CYP2C19, CYP1A2, and CYP2C9. Therefore, we evaluated the effects of CYP2C19 genetic polymorphisms on the pharmacokinetics of zolpidem

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门